Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
220100.KQ
STRONG SELLREMOVEFutureChem Co.,Ltd · Healthcare · South Korea · $222M · Avg Vol: $1M/d
FutureChem specializes in radiopharmaceuticals for cancer diagnosis and treatment. Despite interesting technology, the company has low quality metrics (Q: 32) and lacks the commercial distribution scale required for a concentrated global fund.
COMPANY DESCRIPTION
FutureChem Co., Ltd. specializes in the development and production of radiopharmaceuticals for diagnosing and treating cancers, including prostate and Alzheimer's disease. The company leverages its proprietary automated synthesis technology to maintain a strong market position in South Korea's molecular imaging sector. It operates as a pioneer in the domestic radiopharmaceutical market with expanding global clinical pipelines.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | — | 8M | 9M | 11M | 12M | 14.1% |
| EPS | — | -0.48 | -0.20 | -0.28 | -0.33 | — |
| Shares | — | 22M | 22M | 22M | 22M | -0.0% |
| Debt | 6M | 8M | 2M | 2M | 5M | -3.0% |
| Equity | — | 46M | 42M | 36M | 36M | -8.0% |
| Op CF | — | -5M | -2M | -2M | -2M | — |
| Inv CF | — | -10M | 13M | -8M | -581,482 | — |
| Fin CF | — | 15M | -7M | 8M | 1M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 220100.KQ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 220100.KQ | FutureChem Co.,Ltd(you) | $222M | 6 | STRONG SELL |
| 003520.KS | Yungjin Pharm. Co., Ltd. | $158M | 10 | STRONG SELL |
| 047920.KQ | HLB Pharmaceutical Co., Ltd. | $257M | 14 | STRONG SELL |
| 067080.KQ | DAE HWA Pharmaceutical Co., Ltd. | $127M | 7 | STRONG SELL |
| 389470.KQ | Inventage Lab, Inc. | $362M | 2 | STRONG SELL |
| 019170.KS | Shinpoong Pharmaceutical Co.,Ltd | $343M | 17 | STRONG SELL |
| 293780.KQ | AptaBio Therapeutics Inc. | $91M | 3 | STRONG SELL |
| 170900.KS | Dong-A ST Co., Ltd. | $256M | 25 | SELL |
| 058820.KQ | CMG Pharmaceutical Co., Ltd. | $107M | 14 | STRONG SELL |
| 000520.KS | Samil Pharmaceutical Co.,Ltd | $105M | 14 | STRONG SELL |
Peer medians: ROE -1.1% · P/E 17.7x · Gross margin 43.6%